Crispr Therapeutics Shares Rally Premarket After Favorable FDA Panel Meeting
By Colin Kellaher
Shares of Crispr Therapeutics jumped nearly 20% in premarket trading Wednesday following a U.S. Food and Drug Administration advisory committee meeting on the proposed gene-editing drug exa-cel from Crispr and partner Vertex Pharmaceuticals that analysts believe paves the way for FDA approval.
Crispr and Vertex are seeking FDA approval of exa-cel in sickle-cell disease, an inherited blood disorder, and a green light would make exa-cel the first approved drug using the gene-editing technology known as Crispr.
The FDA often turns to advisory committees to obtain advice from experts who work outside of the government when a scientific, technical or policy question arises, such as whether an unapproved product is safe and effective.
The advisory committee meeting on Tuesday, which unusually didn't include a vote on exa-cel, focused on the drug's potential off-target effects.
In a research note, analysts at Citigroup said the overwhelming consensus from the discussion was that benefit/risk for exa-cel is exceedingly favorable, and that they expect an FDA approval with off-target monitoring language.
Analysts at Truist and Mizuho also said they expect an approval from the FDA, which has set a Dec. 8 target action date.
Trading in Crispr shares was halted Tuesday while the advisory committee held its all-day meeting. The shares, which closed Monday at $38.93, were recently up 19% to $46.30 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 01, 2023 06:14 ET (10:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
3 Cheap and Dependable Dividend-Growth Stocks to Buy
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?